CYTOGEN CORP
10-Q, EX-27, 2000-08-11
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: CYTOGEN CORP, 10-Q, EX-10.1, 2000-08-11
Next: CERPROBE CORP, 10-Q, 2000-08-11



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2000 AND THE CONSOLIDATED STATEMENTS
OF OPERATIONS FOR THE  SIX-MONTH PERIOD ENDED JUNE 30, 2000 AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   JUN-30-2000
<CASH>                                          10,463,000
<SECURITIES>                                             0
<RECEIVABLES>                                    2,445,000
<ALLOWANCES>                                      (61,000)
<INVENTORY>                                        810,000
<CURRENT-ASSETS>                                 1,326,000
<PP&E>                                           8,220,000
<DEPRECIATION>                                 (6,135,000)
<TOTAL-ASSETS>                                  17,939,000
<CURRENT-LIABILITIES>                            5,525,000
<BONDS>                                                  0
                                    0
                                              0
<COMMON>                                           728,000
<OTHER-SE>                                       9,233,000
<TOTAL-LIABILITY-AND-EQUITY>                    17,939,000
<SALES>                                          3,494,000
<TOTAL-REVENUES>                                 4,648,000
<CGS>                                            1,911,000
<TOTAL-COSTS>                                    4,364,000
<OTHER-EXPENSES>                                 5,086,000
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                 109,000
<INCOME-PRETAX>                                (4,548,000)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                            (4,548,000)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                   (4,548,000)
<EPS-BASIC>                                       (0.06)
<EPS-DILUTED>                                       (0.06)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission